The Dangers of Synthetic Marijuana: Rising Cases of Poisoning and Death

Aug.09.2022
The Dangers of Synthetic Marijuana: Rising Cases of Poisoning and Death
Synthetic marijuana is dangerous and can cause severe reactions such as seizures, heart problems, and death. It is a growing problem globally.

On August 5, 2015, a man was preparing to smoke K2, a synthetic marijuana drug, on a street in East Harlem, New York City.


Synthetic cannabis, sold under catchy names such as AK-47, K2, Spice, and Scooby Snacks, is far from being a dreamy substance. Most synthetic cannabinoids are packaged in electronic cigarettes, juices, or foods, and sold as dried plant material that has been sprayed with solvents containing laboratory-made psychoactive substances such as acetone, preservatives, or other chemicals.


According to data from the ToxIC case registry, cases of synthetic cannabis poisoning were on the rise between 2010 and 2015, with over 42,000 reported toxic exposure cases during that period. However, Tracy Klein, the assistant director of the Cannabis Policy, Research and Outreach Center at Washington State University in Vancouver, suggests that these numbers may now be decreasing in states where recreational marijuana use is allowed.


She was the lead author of a study that found that in states where recreational marijuana had been legalized between 2016 and 2019, calls to poison control center related to synthetic marijuana decreased by over one-third.


These products are in powder form, which can be sprayed or added to substances that look exactly like natural marijuana. Therefore, in party situations, I can see how someone could accidentally use it," said Klein, who is also an associate professor at the WSU College of Nursing.


However, according to the Centers for Disease Control and Prevention in the United States, people may also use synthetic cannabinoids "in an attempt to avoid positive drug screenings for employment, drug abuse treatment programs, or the criminal justice system.


A fatal issue/problem.


Over the past decade, thousands of people have been rushed to the emergency room due to marijuana use. According to the Centers for Disease Control and Prevention, some individuals have even died, including a 17-year-old boy who reportedly experienced cardiac arrest after using K2/spice marijuana once.


Experts say it is impossible to know what synthetic cannabinoids are actually present in purchased products or what other substances might be present in solvents used to soak and dry plants.


In April 2018, 153 people in Illinois fell ill and four died after using synthetic marijuana that was laced with rat poison. Later that year, in New Haven, Connecticut, K2 marijuana caused 95 people to become ill within two days. They experienced symptoms such as nausea, vomiting, lethargy, and loss of consciousness.


Klein explained that these synthetic products are officially known as "synthetic cannabinoid receptor agonists," which are different from synthetic marijuana products that have medical uses.


They do not appear in standard drug tests," she said. "The body also does not recognize them in any way that has a positive effect.


This research was published on Tuesday in the Clinical Toxicology Journal, analyzing data from the National Poison Data System between 2016 and 2019. The researchers discovered that over these three years, there were 7600 calls relating to the use of synthetic cannabinoids. Approximately 65% of calls made to poison centers concerned situations requiring medical care, with 61 fatalities reported.


A study has revealed that over half of the calls made to poison control centers (56%) were from states with restrictions on marijuana policies. According to the study, nearly one-third (38.6%) of calls were made from states that allow drug use for medical purposes, while 5.5% were from "permissive" states where recreational use is legal.


The working principle of synthetic cannabinoids.


The Centers for Disease Control and Prevention (CDC) stated that synthetic cannabinoids were first developed in the 1980s for the purpose of studying how tetrahydrocannabinol (THC), the psychoactive ingredient in marijuana, affects the brain in producing high levels.


Klein stated, "A specific synthetic marijuana was designed by a pharmaceutical company as a potential pain relief medication. People discovered that it was so potent and had so many side effects that it was not being abused.


Today, synthetic materials are mainly produced overseas and transported to the United States. In fact, according to the Centers for Disease Control, the first shipment of "goods identified as containing synthetic cannabinoids was seized at the U.S. border in 2008.


This is not just a problem in the United States. It has become an international issue", stated Klein. He pointed out that, as of February 2022, data on illegal markets listed at least 320 different types of synthetic cannabinoids being sold.


She added, "These are only those that have been reported and identified.


Klein stated that, although different from natural cannabis, synthetic compounds do indeed act on the same cannabinoid receptors as THC. However, due to the manner in which they bind to brain receptors, their potency can increase up to 100 times.


Exposure could lead to a range of neurological reactions, from mild to severe, such as agitation and depression in the central nervous system, which could even result in coma. The Centers for Disease Control and Prevention highlight other symptoms including "fatigue, irritability, confusion, dizziness, lack of coordination, inability to concentrate, stroke and seizures.


The agency stated that symptoms of mental illness include "hallucinations, delusions, psychosis, violent behavior, and suicidal thoughts." "Other physical signs and symptoms include shortness of breath, tachycardia, hypertension, severe nausea and vomiting, chest pain and heart attack, rhabdomyolysis (damaged muscles rupturing), kidney failure, and death.


The Disease Prevention and Control Center stated that there is no antidote for synthetic cannabinoid toxicity, and the long-term effects are still unknown. Treatment options include intravenous fluids, oxygen therapy, airway protection, and medication for anxiety and aggression, but these treatments are only supportive measures.


Announcement:


This article has been compiled from third-party sources and is intended solely for industry knowledge and exchange.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is solely for industry communication and research.


Due to limitations in the level of translation ability, the translated article may not express the same meaning as the original. Please refer to the original text for accuracy.


2FIRSTS fully aligns with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and international issues and positions.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
China exported $979 million of vape-related products in August 2026, up 3.3% from a year earlier but down 6.4% from July. The UK replaced the U.S. as the main source of growth: UK-bound shipments jumped 51.4% to a 2026 high of $177 million, while exports to the U.S. fell 12.4% to $339 million. Shipments to markets outside the U.S. increased 14.2%, broadening growth beyond the market that had driven July’s rebound.
News
Sep.23 by 2Firsts Perspectives
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Japan Tobacco Inc. (JT) announced on November 12, 2026, that it had acquired the U.S. assets of nicotine pouch brand CLEW from Nevcore Innovations Inc., including trademarks, intellectual property, product formulations and a Premarket Tobacco Product Application (PMTA). CLEW, currently distributed through selected outlets in 13 U.S. states, will immediately join the JTI LIGGETT portfolio. The transaction follows JT's approximately $2.4 billion acquisition of U.S. cigarette maker Vector Group in 2024. JTI LIGGETT says its existing cigarette brands reach more than 160,000 U.S. retail stores. During the 2026 NACS Show in October, JTI LIGGETT booth staff told 2Firsts that the company had not yet launched nicotine pouches in the United States. Although Nevcore previously announced FDA acceptance of CLEW's PMTA, the brand is absent from the agency's current list of authorized nicotine pouch products. JT has not disclosed a retail expansion plan for CLEW.
Business
Nov.12
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Vaping brand PIXL has introduced the PIXL 5K reusable prefilled pod device in the UK, featuring a 2ml prefilled pod and a 4ml refill container with a combined e-liquid capacity of 6ml. The device uses 20mg/ml nicotine salt e-liquid and is advertised to deliver up to approximately 5,000 puffs. Available through UK retailers by August 2026, the PIXL 5K sits alongside the existing 12ml PIXL 8000. The UK's Vaping Products Duty took effect on October 1 at £0.22 per millilitre, producing theoretical duty amounts of £1.32 and £2.64 for the two products' respective full refill sets.
product
Oct.10
Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
A September online survey commissioned by Japanese smoking-accessories company Lightec found that 49.5% of respondents would consider reducing tobacco use if prices rose further, while 25.1% would consider switching to cheaper brands and 14.5% would consider using or combining alternatives such as vapes and nicotine-free herbal sticks. Another 64.6% expressed some level of interest in such alternatives. The survey covered 1,088 respondents aged 20 to 70 and was conducted by a company that sells NICOLESS nicotine-free vaping and herbal-stick products, meaning its findings should not be treated as representative of Japan's smoking population.
DATA
Oct.12
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30